Lymphoma Working Party (LWP)
Study type:
Study number:
84032213
Type of treatment:
Autologous
Diseases:
Hodgkin’s Disease (HD)
Short title:
Outcome of Autologous HCT after CPIs in HL
Primary objective:
Progression free survival after AHSCT
Key inclusion criteria:
a. Adult patients (age at transplant ≥ 18 years)
b. Classical HL
c. First AHSCT between 2015 and 2022
d. Failure of the first line chemotherapy with/without BV
e. Salvage therapy with CPIs (as single agent or in combination with chemotherapy) as ³ second line
before autologous transplantation
f. Patients also receiving other treatments between CPIs and ASCT
b. Classical HL
c. First AHSCT between 2015 and 2022
d. Failure of the first line chemotherapy with/without BV
e. Salvage therapy with CPIs (as single agent or in combination with chemotherapy) as ³ second line
before autologous transplantation
f. Patients also receiving other treatments between CPIs and ASCT
Country:
All EBMT member countries
Principal investigator:
Carmen Martínez
EBMT Study coordinator:
Irma Khvedelidze
Study coordinator email:
irma.khvedelidze@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Patients’ data is needed to be able to identify the patient and calculate age at any time (impact on SAEs and response to clinical medications). Health care personal data is part of the CV collected for evidence of proper qualification for running the trial.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results